TY - JOUR T1 - MicroRNA Signature for HER2-positive Breast and Gastric Cancer JF - Anticancer Research JO - Anticancer Res SP - 3807 LP - 3810 VL - 34 IS - 7 AU - JOSEPH KIM AU - SANG-GEUN JANG AU - SUN YOUNG KWON AU - YOUNG SOO PARK AU - HAN SUNG KANG AU - JEFFREY E. GREEN AU - HARK KYUN KIM AU - JUNGSIL RO Y1 - 2014/07/01 UR - http://ar.iiarjournals.org/content/34/7/3807.abstract N2 - Background/Aim: The molecular mechanism for aggressive clinical behaviour related to v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) amplification is not fully-understood. In particular, little is known about microRNAs in the human epidermal growth factor receptor 2 (HER2) signaling network. Patients and Methods: Using microRNA microarray, the microRNA profiles of 16 HER2-positive breast carcinomas were compared with those of five luminal-type breast carcinomas. Additionally, two frozen, ERBB2-amplified gastric carcinomas were compared with their adjacent normal tissue samples. MicroRNAs that were differentially expressed according to the HER2 status in breast and gastric carcinomas were identified as the HER2 microRNA signature. Results: MiR-337 and miR-302f were commonly overexpressed in HER2-postive breast and gastric cancer. MiR-139 and miR-129 were commonly underexpressed in HER2-positive breast and gastric cancer. A concordant pattern of microRNA expression was noted between discovery sets and the majority of candidate microRNAs (two out of three) in three validation sets. Conclusion: Our study identified novel microRNAs that were differentially expressed according to the HER2 status across different tumor types. ER -